Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Not pending/lapsed |
21 | DE file number | DAKZ | 60 2011 054 679.1 |
96 | EP file number | EAKZ | 15 19 0823.3 |
97 | EP publication number | EPN | 3017811 |
54 | Designation/title | TI | APIXABAN-FORMULIERUNGEN |
51 | IPC main class | ICM (ICMV) | A61K 9/20 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | A61K 31/4545 (2006.01), A61P 7/02 (2006.01) |
22 | DE application date | DAT | Feb 24, 2011 |
96 | EP application date | EAT | Feb 24, 2011 |
43 | Date of first publication | OT | May 11, 2016 |
| Date of publication of grant | PET | Dec 5, 2018 |
71/73 | Applicant/owner | INH | Bristol-Myers Squibb Holdings Ireland Unlimited Company, Steinhausen, CH; Pfizer Inc., New York, N.Y., US |
72 | Inventor | IN | PATEL, Jatin, Princton, NJ New Jersey 08543, US; FROST, Charles, Princton, NJ New Jersey 08543, US; JIA, Jingpin, Princton, NJ New Jersey 08543, US; VEMA-VARAPU, Chandra, Princton, NJ New Jersey 08543, US |
| Address for service | | Marks & Clerk (Luxembourg) LLP, 1017 LUXEMBOURG, LU |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 308056 P Feb 25, 2010
|
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003017811 Searchable text:
EP000003017811 Original document:
EP000003017811B1 Searchable text:
EP000003017811B1 |
43 | Date of first publication | EVT | May 11, 2016 |
| Date of the first transfer into DPMAregister | EREGT | Jun 24, 2016 |
| Date of the (most recent) update in DPMAregister | REGT | Jul 17, 2025 (Show all update days)(Hide all update days)- Jul 17, 2025
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 05.12.2018: new
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 05.12.2018: deleted
- Aug 1, 2024
- St.36: changed (technical change)
- Jun 24, 2016
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 5)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | May 16, 2019 |
| Issue number | HN | 26 |
| Year | PJ | 2019 |
| Publication date | VT | Jun 27, 2019 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Bristol-Myers Squibb Holdings Ireland Unlimited Company, Steinhausen, CH; Pfizer Inc., New York, N.Y., US |
71/73 | Previous applicant/owner | INHF | Bristol-Myers Squibb Holdings Ireland, Steinhausen, CH, Pfizer Inc., New York, N.Y., US |